JP2008520591A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008520591A5 JP2008520591A5 JP2007541607A JP2007541607A JP2008520591A5 JP 2008520591 A5 JP2008520591 A5 JP 2008520591A5 JP 2007541607 A JP2007541607 A JP 2007541607A JP 2007541607 A JP2007541607 A JP 2007541607A JP 2008520591 A5 JP2008520591 A5 JP 2008520591A5
- Authority
- JP
- Japan
- Prior art keywords
- therapeutic agent
- agent according
- clusterin
- oligonucleotide
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US52294804P | 2004-11-23 | 2004-11-23 | |
| US60/522,948 | 2004-11-23 | ||
| US52296004P | 2004-11-24 | 2004-11-24 | |
| US60/522,960 | 2004-11-24 | ||
| PCT/CA2005/001775 WO2006056054A1 (en) | 2004-11-23 | 2005-11-22 | Treatment of cancer with a combination of an agent that perturbs the egf signaling pathway and an oligonucleotide that reduces clusterin levels |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008520591A JP2008520591A (ja) | 2008-06-19 |
| JP2008520591A5 true JP2008520591A5 (https=) | 2008-11-27 |
| JP4980919B2 JP4980919B2 (ja) | 2012-07-18 |
Family
ID=36497699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007541607A Expired - Fee Related JP4980919B2 (ja) | 2004-11-23 | 2005-11-22 | Ｅｆｇシグナル伝達経路を混乱させる薬剤とクラステリンレベルを減少させるオリゴヌクレオチドとの併用による癌の治療 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20080014198A1 (https=) |
| EP (1) | EP1814595B1 (https=) |
| JP (1) | JP4980919B2 (https=) |
| AU (1) | AU2005309274B2 (https=) |
| CA (1) | CA2584646C (https=) |
| DK (1) | DK1814595T3 (https=) |
| ES (1) | ES2456017T3 (https=) |
| PL (1) | PL1814595T3 (https=) |
| PT (1) | PT1814595E (https=) |
| SI (1) | SI1814595T1 (https=) |
| WO (1) | WO2006056054A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100768109B1 (ko) | 1999-02-26 | 2007-10-17 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법 |
| US7569551B2 (en) * | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| WO2005094899A1 (en) | 2004-04-02 | 2005-10-13 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
| DK1814595T3 (da) * | 2004-11-23 | 2014-03-31 | Univ British Columbia | Behandling af cancer med en kombination af et middel, som forstyrrer EGF-signalvejen og et oligonucleotid, som reducerer clusterinniveauerne |
| AU2006291990B2 (en) * | 2005-09-13 | 2012-05-31 | National Research Council Of Canada | Methods and compositions for modulating tumor cell activity |
| CN102666585B (zh) | 2009-11-24 | 2015-02-18 | 阿莱斯亚生物疗法股份有限公司 | 抗簇蛋白抗体和抗原结合片段及其减小肿瘤体积的用途 |
| WO2012123823A1 (en) | 2011-03-15 | 2012-09-20 | The University Of British Columbia | Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer |
| WO2013123588A1 (en) * | 2012-02-22 | 2013-08-29 | Alethia Biotherapeutics Inc. | Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer |
| MD20140101A2 (ro) * | 2013-02-22 | 2015-02-28 | Alethia Biotherapeutics Inc. | Utilizarea concomitentă a unui inhibitor al clusterinei cu un inhibitor al EGFR pentru tratamentul cancerului |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721237A (en) * | 1991-05-10 | 1998-02-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties |
| US5646042A (en) * | 1992-08-26 | 1997-07-08 | Ribozyme Pharmaceuticals, Inc. | C-myb targeted ribozymes |
| US5417978A (en) * | 1993-07-29 | 1995-05-23 | Board Of Regents, The University Of Texas System | Liposomal antisense methyl phosphonate oligonucleotides and methods for their preparation and use |
| US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
| US6365345B1 (en) * | 1993-12-23 | 2002-04-02 | Biognostik Gesellscahft Für Biomokekulare Diagnostik mbH | Antisense nucleic acids for the prevention and treatment of disorders in which expression of c-erbB plays a role |
| AUPM672594A0 (en) * | 1994-07-08 | 1994-08-04 | Royal Children's Hospital Research Foundation | A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders |
| US5789389A (en) * | 1995-03-17 | 1998-08-04 | Board Of Trustees Of University Of Illinois | BCL2 derived genetic elements associated with sensitivity to chemotherapeutic drugs |
| US5855911A (en) * | 1995-08-29 | 1999-01-05 | Board Of Regents, The University Of Texas System | Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides |
| ATE267207T1 (de) * | 1996-02-14 | 2004-06-15 | Isis Pharmaceuticals Inc | Kohlenhydratmodifizierte luckenhafte oligonukleotide |
| US5910583A (en) * | 1996-11-04 | 1999-06-08 | Duke University | Antisense oligonucleotides against ERBB-2 |
| US6383808B1 (en) | 2000-09-11 | 2002-05-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of clusterin expression |
| US6335194B1 (en) * | 1998-09-29 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of survivin expression |
| US6172216B1 (en) * | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
| US6900187B2 (en) * | 1999-02-26 | 2005-05-31 | The University Of British Columbia | TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications |
| KR100768109B1 (ko) * | 1999-02-26 | 2007-10-17 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 테스토스테론이 억제된 전립선 메시지-2의 안티센스치료방법 |
| US5998148A (en) * | 1999-04-08 | 1999-12-07 | Isis Pharmaceuticals Inc. | Antisense modulation of microtubule-associated protein 4 expression |
| US7569551B2 (en) * | 2000-02-25 | 2009-08-04 | The University Of British Columbia | Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides |
| WO2002097114A2 (en) * | 2001-05-29 | 2002-12-05 | Sirna Therapeutics, Inc. | Nucleic acid treatment of diseases or conditions related to levels of ras, her2 and hiv |
| AU2003237616B2 (en) * | 2002-01-17 | 2007-07-05 | The University Of British Columbia | Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same |
| US7019017B2 (en) * | 2002-05-14 | 2006-03-28 | Baylor College Of Medicine | Small molecule inhibitors of HER2 expression |
| NZ538288A (en) * | 2002-08-21 | 2008-04-30 | Univ British Columbia | Treatment of melanoma by reduction in clusterin levels |
| JP4717633B2 (ja) * | 2002-08-21 | 2011-07-06 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | 癌関連タンパク質を標的とするＲＮＡｉプローブ |
| US20040224914A1 (en) * | 2003-04-18 | 2004-11-11 | The University Of British Columbia | Method for treatment of angiogenic disorders |
| WO2004092378A2 (en) * | 2003-04-18 | 2004-10-28 | The University Of British Columbia | Method for treatment of cancerous angiogenic disorders |
| WO2005094899A1 (en) * | 2004-04-02 | 2005-10-13 | The University Of British Columbia | Clusterin antisense therapy for treatment of cancer |
| DK1814595T3 (da) * | 2004-11-23 | 2014-03-31 | Univ British Columbia | Behandling af cancer med en kombination af et middel, som forstyrrer EGF-signalvejen og et oligonucleotid, som reducerer clusterinniveauerne |
-
2005
- 2005-11-22 DK DK05810600.6T patent/DK1814595T3/da active
- 2005-11-22 PL PL05810600T patent/PL1814595T3/pl unknown
- 2005-11-22 PT PT58106006T patent/PT1814595E/pt unknown
- 2005-11-22 EP EP05810600.6A patent/EP1814595B1/en not_active Expired - Lifetime
- 2005-11-22 US US11/718,815 patent/US20080014198A1/en not_active Abandoned
- 2005-11-22 WO PCT/CA2005/001775 patent/WO2006056054A1/en not_active Ceased
- 2005-11-22 JP JP2007541607A patent/JP4980919B2/ja not_active Expired - Fee Related
- 2005-11-22 SI SI200531838T patent/SI1814595T1/sl unknown
- 2005-11-22 AU AU2005309274A patent/AU2005309274B2/en not_active Ceased
- 2005-11-22 CA CA2584646A patent/CA2584646C/en not_active Expired - Fee Related
- 2005-11-22 ES ES05810600.6T patent/ES2456017T3/es not_active Expired - Lifetime
-
2010
- 2010-09-20 US US12/886,027 patent/US20110142827A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102443358B1 (ko) | 근위축증 및 근긴장성 이영양증을 치료하는 조성물 및 방법 | |
| JP6814788B2 (ja) | Ｃｄ２７４／ｐｄ−ｌ１遺伝子の発現を阻害するための組成物および方法 | |
| ES2709495T3 (es) | Modulación de la expresión del transductor de señales y activador de la transcripción 3 (stat3) | |
| JP2023093644A (ja) | アンジオテンシノーゲンの発現を調節するための化合物及び方法 | |
| EA015570B1 (ru) | Фармацевтическая композиция | |
| WO2015011694A2 (en) | Isotopologues of smad7 antisense oligonucleotides | |
| EA029137B1 (ru) | Модулирование экспрессии вируса гепатита в (hbv) | |
| EA009670B1 (ru) | МОДУЛИРОВАНИЕ ЭКСПРЕССИИ eIF4E | |
| CN104755621A (zh) | 癌症治疗 | |
| CN113544271B (zh) | Malat1表达的调节剂 | |
| JP2005530486A5 (https=) | ||
| JP2006502243A5 (https=) | ||
| JP2015503608A (ja) | ベータ−カテニン関連疾患を処置するための有機組成物 | |
| JP7275164B2 (ja) | Ｅｚｈ２発現の調節因子 | |
| JP2008520591A5 (https=) | ||
| JP2007533742A5 (ja) | 癌治療のためのスルビビンオリゴヌクレオチドおよびゲムシタビンを含む組成物 | |
| JP6722586B2 (ja) | アンチセンス抗悪性腫瘍剤 | |
| TW201016222A (en) | RNA antagonists targeting GLI2 | |
| CN113795581A (zh) | 具有缩短的有义链的双链核酸抑制剂分子 | |
| JP4980919B2 (ja) | Ｅｆｇシグナル伝達経路を混乱させる薬剤とクラステリンレベルを減少させるオリゴヌクレオチドとの併用による癌の治療 | |
| KR20150086442A (ko) | ANT2 siRNA를 함유하는 HER2 표적 항암제에 대한 내성 극복을 위한 조성물 | |
| WO2021157730A1 (ja) | 核酸医薬とその使用 | |
| JP7216381B2 (ja) | Ｒｎａ作用抑制剤及びその利用 | |
| TW201102073A (en) | RNA antagonists targeting GLI2 for the treatment of leukemia | |
| HK40077247A (en) | Antisense oligonucleotide sequences for silencing the human l1-met transcript in tumours |